<p><strong>Professor Michaela Rumlová, head of a research group of the National Institute of Virology and Bacteriology at UCT Prague (and Vice-Rector for doctoral studies), holder of a licensed patent &nbsp;for antiretroviral testing assays, and recipient of the Czech Science Foundation’s President’s Award for HIV research, has also become the principal investigator of the bilateral INTER-EXCELLENCE II project “</strong><i><strong>Cellular factors regulating the export and packaging of unspliced ​​retroviral RNA</strong></i><strong>”, starting this year. In this interview, she explains how retroviruses such as HIV “hack” the cell in order to export their own genome from the nucleus into the cytoplasm, and then to the site where it is specifically packaged into nascent viral particles, a key step in viral replication. Her team is collaborating with the NIH (National Institutes of Health) and Rockefeller University to elucidate mechanisms that may help reveal new vulnerable points in the retrovirus replication cycle while simultaneously clarifying related cellular processes.</strong></p><h5><strong>Could you describe your project and its main objectives?</strong></h5><p>Retroviruses, such as HIV, are viruses that carry genetic information in the form of RNA; however, after entering a cell, they are able to reverse transcribe it into DNA and integrate it into the host genome. In order to replicate, they must transport their genetic information—in the form of unspliced RNA—from the nucleus into the cytosol. There, it serves both as a template for the production of viral proteins and as the genome of new viral particles. This is highly unusual, as the cell very carefully controls which RNA molecules are allowed to leave the nucleus. Normal protein-coding cellular RNAs, known as messenger RNAs (mRNAs), must undergo splicing—a processing step in which certain segments are removed—before being exported. When this process fails, mRNA that retains these segments is held back in the nucleus as part of quality control and subsequently degraded. Retroviruses have managed to outwit this cellular control machinery, allowing their unspliced RNA to pass into the cytoplasm.</p><p>Our project focuses on identifying the cellular proteins that assist retroviruses in this step and on the mechanism by which protein complexes bound to viral RNA are remodelled during RNA transport. The goal is to understand how the virus uses cellular mechanisms to its advantage and how this pathway is linked to the subsequent fate of the RNA, i.e. to its translation and packaging into new viral particles.</p><h5><strong>Why is this export of unspliced ​​RNA so important for retroviral replication?</strong></h5><p>Because this RNA has a dual role for the virus. On the one hand, it serves as a template for synthesizing viral proteins in the cytoplasm; on the other, it represents the genetic material itself, which must be packaged into new viral particles. The virus must package its RNA genome in its unspliced form, as only this RNA contains essential sequences without which further viral replication would be impossible.</p><p><strong>Simply put: </strong>the virus needs to get a complete copy of its genetic instructions out of the nucleus. Once the viral RNA is in the cytoplasm, it can be used as a template for synthesizing viral proteins; and a portion of these RNA molecules is then selected and packaged into a new particle as a genome. We are interested in how the virus forces the cell to allow viral RNA that is, from the cell’s perspective, “unfinished,” that is unspliced, to leave the nucleus. We are also investigating how the cell and the virus together - albeit unintentionally from the cell’s perspective - determine which RNA molecule will be translated into proteins and which will be packaged as the genome. This is one of the key, yet still not fully understood, steps of retroviral replication.</p><h5><strong>What do you think it was about your project that impressed the Ministry of Education, Youth and Sports’ jury the most?</strong></h5><p>I believe the decisive factor was a combination of several elements. First, the reviewers were primarily interested in the scientific problem itself. We are investigating a mechanism that is essential for retroviruses, but still not sufficiently understood, which may also have broader implications for the regulation of cellular processes. In addition, the quality of the team, our strong collaboration with the<strong> NIH </strong>and <strong>Rockefeller University</strong>, and the use of modern methods that will allow us to track viral RNA in great detail also played a role. It was also important that the project has clear objectives and a realistic plan.</p><h5><strong>How will this research contribute to the development of new treatments for retroviral infections?</strong></h5><p>It is important to say that this is primarily basic research. Rather than developing a new drug directly, we are trying to understand, at the molecular level, the step that the virus cannot do without. Only when we fully understand the mechanism of these cellular processes and identify the essential factors for the export of unspliced ​​RNA and how they function, will we be able to better determine which interactions or mechanisms represent potentially vulnerable points. Similar mechanisms associated with the export of unspliced ​​mRNA also appear in some diseases, such as cancer, so I &nbsp;see the benefit of our research mainly in that it will refine our understanding of these pathological processes in the cell, and retroviruses help us do so. Therefore, our work on retroviruses not only shows us how the virus works, but also how the cell itself works.</p><h5><strong>What responsibilities does your UCT Prague team have? How does the collaboration with your American partners work?</strong></h5><p>At UCT Prague, we are conducting the project’s primary experimental work. Our research involves cell cultures, viral models, and various biochemical techniques ranging from immunochemistry to microscopy that allow us to track viral RNA and identify its cellular partners. In collaboration with colleagues from <strong>NIH, Frederick</strong>, we are developing single-particle tracking methods to observe viral RNA movement in living cells across both space and time. Furthermore, we are working with colleagues from <strong>Rockefeller University to employ iCLIP </strong>methods for the precise mapping of protein-binding sites on RNA. Both collaborations are valuable to us, because they are not just about data sharing, but also about the transfer of expertise and detailed know-how.</p><h5><strong>Who else is collaborating on the project?</strong></h5><p>At UCT Prague, we collaborate closely with the Department of Biotechnology and the Department of Biochemistry and Microbiology. Externally, we work with colleagues from the Institute of<strong> Organic Chemistry and Biochemistry of the CAS (IOCB Prague)</strong> and the <strong>Central European Institute of Technology in Brno (CEITEC)</strong>. Our research naturally necessitates the integration of diverse fields of expertise; it requires combining virology, cell biology, and biochemistry with advanced imaging and modern approaches to study RNA-protein interactions. This is exactly what makes our project capable of addressing complex questions that a single laboratory cannot tackle on its own.</p><h5><strong>Are there plans to continue the project? Have you brought on new collaborators, and are you looking to welcome new colleagues to the team?</strong></h5><p>Yes, definitely. In basic research, it often happens that one answered question opens up several more. High-quality, properly interpreted data provide a foundation you can build on — and that is what moves scientists forward. It is already clear that the topic of retroviral RNA export and packaging has broader implications and may reveal more general principles of how RNA functions within the cell. We also hope the project will be attractive to students, as it connects classical molecular biology, biochemistry, and virology with cutting-edge biotechnological methods. Students are already involved in the project as part of their bachelor’s and master’s theses.</p><h5><strong>What was the personal turning point that motivated you to pursue a long-term investigation into retroviral particles?</strong></h5><p>I first encountered retroviruses in the early 1990s during my diploma thesis, when I was working at IOCB Prague on HIV-1 protease inhibitors. At that time, AIDS could not yet be effectively treated, and retrovirus research had a completely different dimension. From the very beginning, I was fascinated by how such a relatively small and simple virus can outsmart evolutionarily highly optimized cellular processes and turn them to its own advantage. And that has never stopped fascinating me. From a scientific point of view, retroviruses are remarkable; just consider one of their enzymes, reverse transcriptase, without which no diagnostic or research laboratory in the world could function today. Without it, it would be impossible to diagnose RNA viruses like SARS-CoV-2, influenza, or HIV using RT-PCR tests, or, for example to produce recombinant human proteins in bacterial cells.</p>

Tracking unspliced RNA: Professor Rumlová studies how retroviruses “hack” cells

<p><strong>High-performance liquid chromatography (HPLC) remains one of the most widely used analytical techniques for separating, identifying, and quantifying compounds in complex mixtures. Successful HPLC method development depends not only on selecting the correct column and optimizing the mobile phase composition, but also on choosing the appropriate detector. Even a perfectly optimized chromatographic separation provides little value if the detection system cannot properly capture and interpret the analytes of interest.</strong></p><p>In many ways, the detector acts as the <i><strong>“vision system</strong></i>” of the chromatograph. It converts separated compounds into measurable electronic signals, allowing analysts to identify components and determine their concentrations. The choice of detector therefore has a major impact on sensitivity, selectivity, robustness, and the overall quality of analytical data.</p><p>This article provides an overview of the most common HPLC detection techniques, discusses their strengths and limitations, and outlines the most important criteria to consider when selecting a detector for a specific analytical task.</p><h3><strong>HPLC Detection Technologies</strong></h3><p>HPLC detectors are typically divided into two major categories:</p><ol><li>Specific detectors (solute-property detectors)</li><li>Bulk property detectors</li></ol><p>Specific detectors respond to a particular chemical or physical property of the analyte. Ideally, their signal is largely unaffected by changes in mobile phase composition. Common examples include UV/Vis detectors, fluorescence detectors, and mass spectrometers.</p><p>Bulk property detectors, on the other hand, measure differences between the pure mobile phase and the mobile phase containing analytes. These detectors are considered more universal because they respond to properties shared by many compounds. Refractive index detectors are among the best-known examples, alongside conductivity and light-scattering detectors.</p><p>Both detector categories have important advantages depending on the application, sample type, and analytical goals.</p><h3><strong>Common Detector Types Used in HPLC</strong></h3><p>A wide variety of detectors are available for HPLC systems, ranging from highly universal devices to extremely selective and sensitive technologies.</p><p>Common detector options include:</p><ul><li>UV/Vis detectors</li><li>Diode array detectors (DAD/PDA)</li><li>Fluorescence detectors</li><li>Refractive index detectors (RID)</li><li>Conductivity detectors</li><li>Evaporative light scattering detectors (ELSD)</li><li>Charged aerosol detectors (CAD)</li><li>Mass spectrometry detectors (MS)</li></ul><p>Each technology offers a different balance of sensitivity, selectivity, robustness, operational complexity, and cost.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Detector_overview_with_characteristics_Graphic_by_KNAUER_84b0dd30b1.jpg" alt="KNAUER: Detector overview with characteristics. Graphic by KNAUER." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Detector_overview_with_characteristics_Graphic_by_KNAUER_84b0dd30b1.jpg 245w," sizes="100vw" width="1293" height="596"></p><h3><strong>Selecting the Right HPLC Detector</strong></h3><p>There is no universally ideal detector for all HPLC applications. The best choice depends on several factors, including analyte chemistry, matrix complexity, required detection limits, and instrument compatibility.</p><p>Careful detector selection is essential for obtaining reliable and meaningful analytical results.</p><p>The following considerations can help guide the selection process.</p><h4><strong>1. Chemical and Physical Properties of the Analytes</strong></h4><p>The chemical nature of the compounds being analyzed is one of the most important selection criteria.</p><p><strong>Questions to consider include:</strong></p><ul><li>Do the analytes contain chromophores?</li><li>Are the compounds naturally fluorescent?</li><li>What is their polarity?</li><li>What is their molecular weight?</li><li>Are they volatile or non-volatile?</li></ul><p>Compounds containing UV-active groups are often well suited for UV/Vis detection, while fluorescent molecules can benefit from the high sensitivity of fluorescence detectors. Non-UV-active compounds may require universal detection approaches such as CAD, ELSD, or mass spectrometry.</p><h4><strong>2. Required Sensitivity</strong></h4><p>Detector sensitivity determines the minimum concentration that can be reliably detected and quantified.</p><p>Routine quality control analyses often rely on UV/Vis detectors because they provide sufficient sensitivity for many applications while remaining relatively simple and cost-effective. However, trace-level analysis or highly complex matrices may require more advanced technologies such as:</p><ul><li>Fluorescence detection</li><li>Charged aerosol detection</li><li>Mass spectrometry</li></ul><p>These techniques offer significantly lower detection limits and greater analytical specificity.</p><h4><strong>3. Detector Linearity</strong></h4><p>Linearity describes how well detector response correlates with analyte concentration across a defined range.</p><p>A detector with strong linearity ensures accurate quantification and simplifies calibration procedures. Poor linearity can introduce quantification errors, especially when analyzing samples across broad concentration ranges.</p><h4><strong>4. Dynamic Range</strong></h4><p>Dynamic range refers to the concentration interval over which the detector can reliably measure analytes.</p><p>Applications involving samples with highly variable concentrations require detectors capable of maintaining accurate response over a broad range. A wide dynamic range reduces the need for repeated dilutions or multiple analytical runs.</p><h4><strong>5. Selectivity</strong></h4><p>Selectivity defines the detector’s ability to distinguish target analytes from other matrix components.</p><p>This factor becomes particularly important for complex samples containing many interfering substances. Highly selective detectors reduce the risk of overlapping signals and false positives.</p><p>Mass spectrometry is often advantageous when dealing with unknown compounds or highly complicated sample matrices because it provides structural information in addition to quantitative data.</p><h4><strong>6. Budget Considerations</strong></h4><p>Detector cost is another practical factor that laboratories must evaluate.</p><p>UV/Vis and refractive index detectors are generally among the more economical choices, making them attractive for routine analyses and standard applications.</p><p>More sophisticated technologies such as fluorescence detection, CAD, or mass spectrometry typically require:</p><ul><li>Higher initial investment</li><li>Additional maintenance</li><li>More complex infrastructure</li><li>Greater operational expertise</li></ul><p>However, the overall value of the detector should always be considered in relation to analytical performance requirements and long-term application needs.</p><h4><strong>7. Instrument and Mobile Phase Compatibility</strong></h4><p>The selected detector must be compatible with the operational conditions of the HPLC system.</p><p>Important parameters include:</p><ul><li>Flow rate range</li><li>Pressure limitations</li><li>Mobile phase composition</li><li>Solvent compatibility</li></ul><p>Some detectors are highly sensitive to mobile phase composition or gradient changes, while others tolerate a broader range of operating conditions.</p><p>Ensuring proper compatibility helps prevent baseline instability, signal interference, and reduced detector performance.</p><h4><strong>8. Destructive vs. Non-Destructive Detection</strong></h4><p>Another important consideration is whether the analytical workflow involves only detection or also preparative purification.</p><p>Non-destructive detectors allow collected fractions to remain intact after detection, which is highly beneficial for preparative chromatography and purification workflows.</p><p>Destructive detectors, by contrast, consume or alter the sample during measurement and are therefore more suitable for analytical applications where sample recovery is not required.</p><h4><strong>9. Reliability and Ease of Operation</strong></h4><p>Practical usability is often just as important as analytical performance.</p><p>Some detectors are designed for straightforward plug-and-play operation, while others require:</p><ul><li>Frequent calibration</li><li>Specialized maintenance</li><li>Dedicated gas supplies</li><li>Vacuum systems</li><li>Advanced operator expertise</li></ul><p>Laboratories should evaluate the available technical support, user experience, and maintenance capabilities before implementing more sophisticated detection technologies.</p><p>Reliable operation and manageable maintenance requirements can significantly improve laboratory productivity and reduce downtime.</p><p>Choosing the correct HPLC detector starts with understanding both the sample and the analytical objective. Rather than selecting a detector simply because it is available, laboratories should ensure that the technology aligns with the chemistry of the analytes, required performance characteristics, and workflow demands.</p><p>In many cases, combining multiple detectors within a single HPLC system can provide even greater analytical insight by delivering complementary information from the same chromatographic separation.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Flow_scheme_for_detector_selection_Graphic_by_KNAUER_486004045f.jpg" alt="KNAUER: Flow scheme for detector selection. Graphic by KNAUER." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Flow_scheme_for_detector_selection_Graphic_by_KNAUER_486004045f.jpg 245w," sizes="100vw" width="1316" height="808"></p><p>Interested in learning more? Future articles will explore individual HPLC detection techniques in greater detail, including their operating principles, application areas, and practical advantages for different analytical workflows.</p>

A comprehensive guide for selecting the appropriate HPLC detector

News from LabRulezLCMS Library - Week 20, 2026

Article

Product

Application

Scientists

Science and research

The University of Chemistry and Technology, Prague is a natural centre of first-rate study and research in the area of chemistry in Czechia and is one of the country's largest educational and research institutions focused on technical chemistry, chemical and biochemical technologies, material and chemical engineering, food chemistry, and environmental studies.

UCT Prague

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

Agilent Technologies

Technology Networks

Phenomenex

SelectScience

SCIEX

Evosep Biosystems

Waters Corporation

<h3><strong>Pharma and biopharma fundamentals masterclasses</strong></h3><h5><strong>Build confidence in your analytical decisions across pharma and biopharma workflows</strong></h5><p>The pharma and biopharma fundamentals masterclasses are a year-long educational series designed for scientists who want to strengthen their knowledge, compare analytical strategies, and apply best practices across regulated workflows.</p><p>Each session focuses on a real analytical challenge — from quantitation and metabolite identification to biopharma characterization and extractables and leachables — with practical guidance from SCIEX experts.</p><p>Attend live or watch on demand and choose the sessions most relevant to your work.</p><h4><strong>Available now:</strong></h4><h5><strong>Pharma fundamentals: Metabolite Identification Metabolite identification is essential in drug discovery, supporting confident decisions in compound design and toxicology</strong></h5><p>This session shows how alternative fragmentation strategies can overcome limitations of traditional CID and improve MetID accuracy for complex metabolites.</p><ul><li><strong>Speaker: </strong>Heather Chassaing, Senior Accurate Mass Workflow Specialist, SCIEX</li></ul><h4><strong>Upcoming sessions</strong></h4><h5><strong>2. Biopharma fundamentals: Fragment analysis by CE</strong></h5><p>This masterclass introduces protein fragment analysis using capillary electrophoresis, with a focus on CE-SDS in biopharmaceutical workflows. Learn the core principles behind size-based separation, along with practical guidance on sample preparation, method optimization, and data interpretation to support reliable characterization and quality control in regulated biopharma environments.</p><blockquote><p><strong>Speaker:</strong> Stephen Lock, Sr. Market Development Manager – Biopharma, SCIEX</p><p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p></blockquote>

SCIEX: Pharma and biopharma fundamentals masterclasses

Biopharma fundamentals: Fragment analysis by CE

Biopharma masterclass on fragment analysis by CE-SDS, covering protein separation, method optimization, and QC in regulated environments.

<h3><strong>Pharma and biopharma fundamentals masterclasses</strong></h3><h5><strong>Build confidence in your analytical decisions across pharma and biopharma workflows</strong></h5><p>The pharma and biopharma fundamentals masterclasses are a year-long educational series designed for scientists who want to strengthen their knowledge, compare analytical strategies, and apply best practices across regulated workflows.</p><p>Each session focuses on a real analytical challenge — from quantitation and metabolite identification to biopharma characterization and extractables and leachables — with practical guidance from SCIEX experts.</p><p>Attend live or watch on demand and choose the sessions most relevant to your work.</p><h4><strong>Available now:</strong></h4><h5><strong>Pharma fundamentals: Metabolite Identification Metabolite identification is essential in drug discovery, supporting confident decisions in compound design and toxicology</strong></h5><p>This session shows how alternative fragmentation strategies can overcome limitations of traditional CID and improve MetID accuracy for complex metabolites.</p><ul><li><strong>Speaker: </strong>Heather Chassaing, Senior Accurate Mass Workflow Specialist, SCIEX</li></ul><h4><strong>Upcoming sessions</strong></h4><h5><strong>3. Pharma fundamentals: To Be or Not to Be? QQQ vs HRMS Quant</strong></h5><p>Discover how QQQ and HRMS stack up for quantitation in bioanalysis, from sensitivity to workflow efficiency. Learn best practices using SCIEX 7500+ and ZenoTOF 7600 systems to make confident, data-driven decisions.&nbsp;</p><blockquote><p><strong>Speaker:</strong> Cathy Lane, Sr. Application Lead, SCIEX</p><p>Cathy joined SCIEX in 2006 as a Support Specialist and in 2021 took up the role of EMEAI Applications Lead for Pharma &amp; Peptide Quant. She has 25 years’ experience in the development of LC-MS methods for the analysis of small and large molecules. She has a PhD in mass spectrometry-based proteomics from the University of London School of Pharmacy, an MSc in Forensic Science from King’s College London and an MA in Chemistry from the University of Oxford.</p></blockquote>

Pharma fundamentals: To Be or Not to Be? QQQ vs HRMS Quant

Pharma masterclass comparing QQQ vs HRMS quantitation with SCIEX 7500+ and ZenoTOF 7600 for confident bioanalysis decisions.

Biopharma fundamentals: LCMS Biopharma characterization

<p><strong>As the global conversation around per‑ and polyfluoroalkyl substances (PFAS) moves beyond environmental detection, a new priority has emerged: accurately characterizing human exposure and biological impact. This requires not only understanding toxicological pathways, but also refining how we measure PFAS, which biomarkers matter most, and how analytical workflows shape health‑risk interpretation.</strong></p><p>Join our expert panel, including advisors to the Department for Environment, Food and Rural Affairs (DEFRA) and the World Health Organization (WHO), as we bridge cutting‑edge analytical science with real‑world clinical and regulatory decision‑making.</p><h4><strong>This session will explore:</strong></h4><ul><li>How advances in LC‑MS/MS, HRMS, and multi‑omics are redefining PFAS biomonitoring</li><li>Which PFAS compounds, metabolites, and exposure biomarkers should be prioritized for meaningful assessment</li><li>How measurement challenges (e.g. ultra‑trace detection, matrix effects, isomer resolution) directly influence toxicological models and global risk assessment</li><li>Emerging analytical strategies supporting evidence‑based legislation and population‑level health protection</li></ul><h4><strong>Who should attend?</strong></h4><ul><li>Analytical chemists developing LC‑MS/MS or HRMS workflows for PFAS exposure and metabolomics</li><li>Toxicologists and clinical researchers integrating analytical data into metabolic and health‑outcome models</li><li>Regulatory and EHS (environmental, health, and safety) professionals evaluating PFAS risk in fast-moving consumer goods, cosmetics, and personal care</li><li>Public health policy makers seeking clarity on which biomarkers and analytical endpoints drive next‑gen legislation</li></ul><h4><strong>Webinar details</strong></h4><ul><li><strong>Cost: </strong>Free to attend</li><li><strong>Location: </strong>Online</li><li><strong>Duration:</strong> 60 minutes</li></ul><h5><strong>Certificate of attendance</strong></h5><ul><li><i>If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.&nbsp;</i></li><li><i>If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.</i></li></ul><blockquote><p><strong>Speaker: </strong>Dr. Anna Lindell (Co-Founder &amp; VP Technology, Cambiotics, Researcher, University of Cambridge)</p><p>Dr. Anna Lindell specializes in the development of biotechnological solutions for environmental remediation. Her research at the University of Cambridge focuses on the molecular mechanisms of contaminant degradation, specifically how biological systems can be leveraged to break down persistent substances.</p><p>As Co-Founder and VP of Technology at Cambiotics, she translates these laboratory findings into scalable technologies designed to address the challenges of PFAS contamination in the field.</p><p><strong>Speaker:&nbsp;</strong>Dr. Mohamed Abdallah (Chair in Environmental Chemistry, University of Birmingham)</p><p>Dr Mohamed Abdallah has extensive experience in applying mass spectrometric techniques for analysis of trace levels of environmental pollutants in biotic and abiotic matrices including different human tissues. He has particular interest in assessing the risk from human exposure to emerging contaminants using various exposure and pharmacokinetic models. Abdallah is also actively engaged in microplastics research.</p><p>Dr Mohamed Abdallah is part of the Birmingham Plastics Network, an interdisciplinary team of more than 40 academics working together to shape the fate and sustainable future of plastics.</p><p><strong>Speaker:&nbsp;</strong>Dr. Luigi Margiotta-Casaluci (Senior Lecturer in Toxicology, King's College London)</p><p>Dr. Luigi Margiotta-Casaluci focuses on the biological impact of environmental stressors through the lens of predictive toxicology. Based at King’s College London, his work utilizes New Approach Methodologies (NAMs) and advanced modeling to evaluate how chemical mixtures interact with human and ecosystem health. By integrating pharmacological principles with toxicological data, he works to define the physiological risks associated with PFAS exposure and inform clinical and regulatory understanding.</p><p><strong>Moderator: </strong>Lucy Lawrence (Science Editor, SelectScience)</p><p>Lucy Lawrence is an NHS-trained haematological biomedical scientist by background, a foundation that informs her work in making complex scientific research accessible to a global audience. As Science Editor at SelectScience, she co-leads the "Accelerating Science in PFAS" initiative, an editorial program examining the full lifecycle of forever chemicals over 2026, from ultra-trace detection and method validation to regulatory compliance and remediation.</p></blockquote>

SelectScience: Advancing PFAS biomonitoring: What we measure and why it matters

Advancing PFAS biomonitoring: What we measure and why it matters

PFAS biomonitoring and risk assessment using LC-MS/MS, HRMS, and multi-omics. Learn how analytical advances guide toxicology and regulation.

Advancing PFAS biomonitoring

<p><strong>In the third webinar of the Small Molecules, Big Impact series, we will explore how MaxPeak Premier Columns are being applied in discovery workflows, with real-world examples of recently approved drug compounds analyzed using this technology.</strong></p><p>Attendees will see how improved surface chemistry can enable more accurate and reliable characterization of in-flight drug products, helping scientists generate high-quality chromatographic data when it matters most. This session is designed for analytical scientists supporting discovery programs who want a deeper understanding of current LC technologies on the market and how MaxPeak Premier Columns can be leveraged to strengthen confidence in their analytical results. Examples will also be given to how Waters technologies can improve throughput using ultra-short columns.</p><h4><strong>Who should attend</strong></h4><ul><li>Analytical scientist supporting discovery groups.</li></ul><h4><strong>Why you should attend</strong></h4><ul><li>Understand how MaxPeak Premier Columns can be used to improve. characterization of new and in-flight drug compounds during discovery workflows</li><li>Review examples of recently approved drugs analyzed with MaxPeak Premier technology and the resulting improvements in chromatographic performance.</li><li>Learn where and how to apply MaxPeak Premier Columns within discovery.&nbsp;</li></ul><h4><strong>What you will walk away with</strong></h4><ul><li>A stronger understanding of how MaxPeak Premier Columns can help characterize new compounds more easily and accurately.</li><li>Expert insights and perspectives on applying this technology to real-world drug development challenges.</li><li>Access to resources that enable you to further evaluate and research MaxPeak Premier technology for your own analytical workflows.</li><li>Learn practical strategies for increasing throughput in discovery experiments, including the use of ultra-short UPLC columns.</li></ul><blockquote><p><strong>Speaker: </strong>Kenneth Berthelette (Principal Scientist, Waters Corporation)</p><p>Ken earned his Bachelor of Science in Professional Chemistry from Bridgewater State University in Bridgewater, Massachusetts in 2010.</p><p>He joined Waters Corporation in March 2012, where he contributed to multiple product launches as part of the Research and Development team. In 2021, Ken transitioned into a role supporting Chemistry Aftermarket initiatives.</p><p>With a strong focus on applications and customer education, he has delivered numerous seminars and webinars covering topics such as method development, method modernization and transfer, HILIC separation techniques, and LC system troubleshooting.</p></blockquote>

Enhancing Next-Gen Drug Discovery with High-Performance Inert LC Solutions

Discover how MaxPeak Premier Columns improve LC analysis of new drugs, enhancing accuracy, performance, and throughput in discovery workflows.

Next-Gen Drug Discovery with Inert LC Solutions

<p><strong>As peptide-based therapeutics continue to expand, understanding and controlling aggregation behavior has become essential for ensuring drug safety and efficacy. This webinar provides a focused exploration of peptide aggregation mechanisms and how Size Exclusion Chromatography (SEC) can be applied to characterize these critical quality attributes. Attendees will be introduced to the separation principles behind SEC and learn how Biozen dSEC‑1 can improve peptide aggregate detection and quantification. Real-world applications will cover aggregation profiles of key GLP‑1 receptor agonists including semaglutide, liraglutide, and tirzepatide.</strong></p><h5><strong>Key Learning Points</strong></h5><ul><li>Learn about the fundamentals of peptide aggregation</li><li>Find the separation mechanism of Size Exclusion Chromatography (SEC)</li><li>Identify the key features and advantages of the Biozen dSEC‑1 column</li><li>Discuss the use of Biozen dSEC-1 for aggregate analysis of GLP-1 agonists (Semaglutide, Liraglutide, and Tirzepatide)</li></ul><h5><strong>Who Should Attend</strong></h5><ul><li>Any LC users working with or interested in analyzing peptide therapeutics by HPLC. &nbsp;</li></ul><blockquote><p><strong>Speaker:</strong> Lucia Geis Asteggiante (Senior Technical Specialist, Phenomenex)</p><p>Lucia is a Senior Technical Specialist that has recently joined Phenomenex’s Global Technical Team. She has a broad experience in the field of Analytical Chemistry with a particular focus on LC chromatography coupled with mass spectrometry. Lucia comes from a strong academic and regulatory background with experiences ranging from method development and analysis of small molecules to large protein complexes. She gained her Ph.D. at the University of Maryland - College Park, USA and did her post-doctoral work at the University of Oxford, UK. During her time as a researcher, she has authored/co-authored 23 scientific publications and 2 book chapters.</p></blockquote>

Phenomenex: Reliable GLP-1 Aggregate Analysis Using Biozen dSEC

Reliable GLP-1 Aggregate Analysis Using Biozen dSEC

This webinar provides an exploration of peptide aggregation mechanisms and how SEC can be applied to characterize these critical quality attributes.

<p><strong>As lipid nanoparticle (LNP)-based therapeutics diversify and regulatory expectations for complex nucleic acid products mature, analytical strategies must evolve. Modern LNP characterization now requires integrated workflows that can simultaneously assess particle size, quantify payload, and detect critical impurities.</strong></p><p>In this SelectScience® webinar, Dr. Mojca Tajnik Sbaizero, a specialist with 10 years of experience in downstream processing for viral and non‑viral delivery, will be joined by Tristan Kovačič, who leads formulation development for non‑viral nucleic acid delivery at Sartorius BIA Separations. Together, they will demonstrate how emerging chromatographic platforms enable multi‑parameter LNP characterization and support robust, scalable analytical strategies across diverse delivery systems. They will also show how these same approaches help generate functional, uniform LNP particles for final drug product development.</p><p>As LNP complexity increases, these experts will outline the growing need to separate distinct particle subpopulations and explain how advanced chromatographic separations enhance consistency, safety, and overall product understanding, ultimately strengthening progress in drug development.</p><h4><strong>Who should attend?</strong></h4><ul><li>Professionals in biopharmaceuticals</li><li>Formulation Scientists</li><li>Healthcare Professionals</li><li>Research and Manufacturing Scientists</li></ul><h4><strong>What will this webinar cover?</strong></h4><ul><li>Chromatographic solutions for LNP drug products across both analytical and preparative scales.</li><li>Practical case studies demonstrating innovative chromatographic technologies applied to multiple LNP formulations.</li><li>How emerging chromatographic strategies enable the separation and characterization of LNP subpopulations.</li><li>How these advances support safer, more consistent, and regulatory-ready LNP therapeutics.</li></ul><blockquote><p><strong>Speaker:&nbsp;</strong>Dr. Mojca Tajnik Sbaizero (Head of Product-Application Area, Sartorius BIA Separations)</p><p>Dr. Mojca Tajnik Sbaizero is Head of Product–Application Area at Sartorius BIA Separations. She is a biotechnologist with a PhD in Biomedicine from the University of Ljubljana. During her PhD and post-doctoral academic work in the UK and Italy, her research focused on pre‑mRNA processing and therapeutic approaches for genetic diseases involving alternative splicing.</p><p>Since joining Sartorius BIA Separations in 2016, she has specialized in downstream processing of viral and non‑viral delivery vectors. She is the author of several scientific publications and a patent in this field, supervises graduate students, and leads the Virus and Nanoparticle Innovation group.</p><p><strong>Speaker:&nbsp;</strong>Tristan Kovačič (Project Manager, Sartorius BIA Separations)</p><p>Tristan Kovačič is a Project Manager at Sartorius BIA Separations, responsible for the development of novel methods for analytics, purification and formulation of non viral delivery of nucleic acids. He has experience in small molecule synthesis and large molecule analytics and formulation, and is passionate about the development of novel pharmaceuticals. He holds an MSci from Imperial College London.</p><p><strong>Moderator: </strong>Olivia Long (Editorial Team, SelectScience)</p><p>As a Science Editor specializing in pharmaceutical and applied research, Olivia Long brings a strong background in experimental biology and scientific communication. She holds a B.Sc. in Pharmacology from the University of Southampton and an M.Sc. in Neuroscience from the University of Sussex, where she investigated neuro‑oncology drug‑resistance pathways using patient‑derived cell models.</p><p>Her broader laboratory experience spans R&amp;D hygiene testing, controlled environment entomology workflows, and protocol development, giving her a practical understanding of diverse analytical and research environments. She is dedicated to translating complex science into clear, engaging content for researchers and industry professionals.&nbsp;</p></blockquote>

Select Science: Revealing hidden LNP subpopulations with high‑resolution chromatographic techniques

Revealing hidden LNP subpopulations with high‑resolution chromatographic techniques

How emerging chromatographic platforms enable multi‑parameter LNP characterization

Revealing hidden LNP subpopulations

<p><strong>PFAS, often referred to as “forever chemicals,” are a diverse class of anthropogenic compounds that have become a major public health concern. Their wide range of structures and frequent presence in laboratory materials create unique analytical challenges. These challenges are especially pronounced for ultra‑short‑chain PFAS, whose high polarity, limited retention on conventional reversed‑phase columns, and tendency to coelute with matrix components make them particularly difficult to separate and quantify.&nbsp;</strong></p><p>In this webinar, we will discuss key considerations for selecting an LC separation technique and choosing appropriate consumables—along with strategies to address the chromatographic complexities of ultra‑short‑chain PFAS—to help streamline PFAS analysis.</p><blockquote><p><strong>Speaker: </strong>Emily Parry, Ph.D.</p><p>Emily Parry holds a Ph.D. in Environmental Chemistry from the University of California, Davis, where she studied how wastewater treatment transforms environmental contaminants. After completing her degree, she began her career conducting research at the Environmental Protection Agency (EPA) and the Public Health Institute. In 2018, she joined Agilent Technologies as an application scientist focused on small‑molecule analysis using LC‑QTOF and LC‑TQ, specializing in environmental applications. In 2026, she transitioned to Agilent’s LC columns group, where she supports customers and applications in small‑molecule separations. Over the years, she has developed deep expertise in analytical methods for measuring small molecules across diverse sample types.</p></blockquote>

Agilent Technologies: Navigating PFAS Complexity: Addressing the Unique Chromatographic Challenges of Ultra‑Short‑Chain PFAS

Navigating PFAS Complexity: Addressing the Unique Chromatographic Challenges of Ultra‑Short‑Chain PFAS

Key considerations for selecting an LC separation technique and choosing appropriate consumables.

Chromatographic Challenges of Ultra‑Short‑Chain PFAS

<p><strong>Environmental labs are facing increasing pressure to address ultrashort-chain PFAS as regulatory scrutiny accelerates and begins to influence current testing priorities. Many still lack clarity on when these compounds matter, how evolving EPA direction and European regulations apply, and how to manage analytical trade-offs.</strong></p><p>This webinar explores real-world measurement challenges and introduces a practical decision framework to support confident, fit-for-purpose strategies. Attendees will gain insight into aligning methods with specific analytical goals, improving reliability while avoiding one-size-fits-all workflows.</p><h4><strong>Attend this webinar to:</strong></h4><ul><li>Understand why ultrashort-chain PFAS are becoming increasingly relevant in environmental analysis</li><li>Recognize how EPA direction and current European regulations may influence USC PFAS testing priorities</li><li>Identify the main analytical and workflow challenges in measuring USC PFAS with confidence</li><li>Apply a practical decision framework to distinguish between screening, quantitation, and compliance-driven needs</li></ul><blockquote><p><strong>Speaker: </strong>Ivan Huang (Small Molecules Analytical Columns Product Manager, Agilent Technologies)</p></blockquote>

Technology Networks: Ultrashort-Chain PFAS: Practical Guidance for Testing Labs

Ultrashort-Chain PFAS: Practical Guidance for Testing Labs

Understand why ultrashort-chain PFAS are becoming increasingly relevant in environmental analysis

<h4><strong>Reduce Measurement Errors and Improve Confidence in pH Results</strong></h4><p><strong>This webinar covers practical approaches to improving pH measurement accuracy in environmental testing, with a focus on avoiding common errors that lead to proficiency testing failures.</strong></p><p>pH is one of the most commonly measured - and most frequently failed -parameters in environmental testing. With tight proficiency testing acceptance limits and strong temperature dependence, even small measurement errors can lead to unacceptable results. This webinar provides a practical, end to end overview of pH measurement, with a focus on improving confidence, consistency, and proficiency testing performance.</p><p>Throughout the presentation, we connect theory to practice with actionable tips that can be applied immediately in the laboratory. Whether you are troubleshooting a recent pH failure or looking to strengthen routine measurement practices, this webinar is designed to help laboratories “get pH right” and improve long term measurement reliability</p><h4><strong>What you will learn:</strong></h4><ul><li>Understand pH fundamentals and regulatory proficiency testing requirements.</li><li>Apply best practices for accurate pH measurement, calibration, and quality control.</li><li>Maintain and troubleshoot pH probes to ensure reliable performance.</li></ul><h4><strong>Who should attend</strong></h4><ul><li>Analytical scientists</li><li>Laboratory managers</li><li>Quality assurance managers</li></ul><blockquote><p><strong>Speaker:&nbsp;</strong>Christy Abbas, PhD (Sr. Product Marketing Manager, Waters ERA)</p><p>Christy has been with Waters ERA for six and a half years. Her career spans roles at an instrument manufacturer, a biopharmaceutical laboratory, and a mining company. She earned her PhD in Applied Chemistry from the Colorado School of Mines.</p><p>Throughout her career, Christy has supported the nuclear, pharmaceutical, and chemical industries, as well as academia. Drawing on her background in analytical chemistry, product development, marketing, and sales, she is focused on expanding Waters ERA’s product portfolio to better meet evolving customer needs.</p></blockquote>

Getting pH Right

Understand pH fundamentals and regulatory proficiency testing requirements.

<p><strong>Get an exclusive pre-ASMS 2026 sneak peek into how Evosep is driving the next phase of proteomics standardization. Building on our Open Innovation Initiative, this webinar will showcase upcoming advancements in Evotip-based sample preparation, harmonized protocols, and integrated workflows designed for scalability and reproducibility -addressing one of proteomics’ biggest challenges: sample preparation.</strong></p><blockquote><p>Speakers to be announced</p></blockquote>

Evosep: Preparing for Next Generation Evosep Proteomics

Preparing for Next Generation Evosep Proteomics

Join Evosep’s pre-ASMS 2026 webinar on proteomics standardization. Explore Evotip advancements and scalable workflows for reproducible sample preparation.